HGF/c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The 43,000-year-old Divje Babe flute (a cave bear femur) from Slovenia has been attributed by some researchers to Neanderthals, though its status as a Palaeolithic flute is heavily disputed. Many researchers consider it to be most likely the product of a carnivorous animal chewing the bone.
== Properties == Confluentic acid is a member of the class of chemical compounds called depsides. Its IUPAC name is 4-[2-hydroxy-4-methoxy-6-(2-oxoheptyl)benzoyl]oxy-2-methoxy-6-pentylbenzoic acid. The ultraviolet absorbance maxima (λmax) has two peaks at 268 and 304 nm. In the infrared spectrum, significant peaks indicative of the carboxylic acid functional group occur at 1700 cm−1 (C=O stretching in carbonyl groups) and within the broad range of 2600 to 3100 cm−1 (O-H stretching). The broad band at 3100 is due to hydrogen bonding, while the peak at 3500 is the COOH stretching band. Confluentic acid's molecular formula is C28H36O8; it has a molecular mass of 500.57 grams per mole. In its purified form, it exists as crystalline needles with a melting point of 157 °C (315 °F).
=== Other pursuits === In November 2023, the first issue of Holy Roller, a comic written by Samberg, Rick Remender, Joe Trohman and illustrated by Roland Boschi, was released and published by Image Comics. It is about a pro bowler who is forced to quit his dream job and return to his hometown, which he soon discovers has been overrun by Neo-Nazis, leading him to become a trick bowling ball-wielding Jewish superhero. Samberg co-hosts The Lonely Island and Seth Meyers Podcast alongside Schaffer, Taccone and Seth Meyers, which discusses the Lonely Island's SNL Digital Shorts.
Pakistani military claimed to have killed 34 TTP militants in engagement throughout Khyber Pakhtunkhwa and Balochistan, with three killed in Lakki Marwat district, 10 killed in Bannu district and 13 killed in North Waziristan as well as eight killed in Zhob district. A police constable was killed in a militant attack in Wana while six police personnel including a DSP were killed and three were wounded in an insurgent ambush in Kohat District. An ex-Police officer and a militant were killed while another militant was injured in an engagement in Peshawar District. On 25 February, local sources reported that further skirmishes took place in Maqbal area in Dand Aw Patan District of Paktia province between Taliban and Pakistani forces. Light clashes took place in Mohmand and Kurram Districts whereas heavy fighting occurred in Khyber District between Pakistani security forces and Pakistani Taliban. Pakistani military claimed to have killed 10 TTP militants in a follow-up operation in Zhob District. Unidentified militants attacked a police patrol in Bajaur killing four and wounding two police personnel and also killed a constable and his son in South Waziristan. On 26 February, at around 20:00 local time (15:30 GMT), Taliban-led Afghanistan's officials announced the launch of what they described as a "retaliatory operation", directed by Defence Minister Mullah Yaqoob and Army Chief Fasihuddin Fitrat, along the border in the provinces of Nangarhar, Nuristan, Kunar, Khost, Paktia, and Paktika.
Sources: en.wikipedia.org
=== Suspended === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist – alcoholism Rocavorexant (C4X-3256; INDV-2000) – orexin OX1 receptor antagonist – opioid-related disorders Tetrodotoxin (9401-TTX; Halneuron; Tectin; Tetrodin; Tocudin) – voltage-gated sodium channel blocker
The main natural sources of muscimol are fungi of the genus Amanita, such as Amanita muscaria (fly agaric) and Amanita pantherina (panther cap). It is produced in the mushrooms along with muscarine (which is present in trace amounts and it is not active), muscazone, and ibotenic acid. In Amanita muscaria, the layer just below the skin of the cap contains the highest amount of muscimol, and is therefore the most psychoactive portion.
Soon after inoculation, yeast begin to rapidly consume the available assimilable nitrogen with up to 46% of YAN being fully consumed by the onset of full fermentation. Because inorganic nitrogen, such as the ammonium salts in DAP, are toxic to yeast in high levels, it is never added during inoculation when the biomass of the newly re-hydrated yeast is low. Many winemakers split up the dosage of DAP with the first addition being made at the end of the lag phase when the yeast enter their period of exponential growth and alcoholic fermentation begins. In most must this is around 48 to 72 hours after inoculation. A second dosage is then often added around a third of the way through sugar fermentation and often before the sugar levels hit 12-10 Brix (6.5 to 5.5 Baumé, 48.3 to 40.0 Oechsle) because as the fermentation progresses yeast cells are no longer able to bring the nitrogen into the cell due to the increasing toxicity of ethanol surrounding the cells. This leaves the nitrogen unused and available for spoilage organisms that may come afterwards.
Following receipt of the test results and after further flights by USAAF pilots, the results were so positive that North American began work on converting several aircraft developing into the P-51B/C (Mustang Mk III) model, which became the first long-range fighter to be able to compete with the Luftwaffe's fighters. The definitive version, the P-51D, was powered by the Packard V-1650-7, a license-built version of the two-speed, two-stage-supercharged Merlin 66, introduced the "bubble" canopy, and was armed with six .50 caliber (12.7 mm) AN/M2 Browning machine guns. From late 1943 into 1945, P-51Bs and P-51Cs (supplemented by P-51Ds from mid-1944) were used by the USAAF's Eighth Air Force to escort bombers in raids over Germany, while the RAF's Second Tactical Air Force and the USAAF's Ninth Air Force used the Merlin-powered Mustangs as fighter-bombers, roles in which the Mustang helped ensure Allied air superiority in 1944. The P-51 was also used by Allied air forces in the North African, Mediterranean, Italian, and Pacific theaters. During World War II, Mustang pilots claimed to have destroyed 4,950 enemy aircraft. At the start of the Korean War, the Mustang, by then redesignated F-51, was the main fighter of the United States until jet fighters, including North American's F-86 Sabre, took over this role; the Mustang then became a specialized fighter-bomber. Despite the advent of jet fighters, the Mustang remained in service with some air forces until the early 1980s. After the Korean War, Mustangs became popular civilian warbirds and air racing aircraft.
=== Dwarf sports === Dwarfs have support and compete in sport by a number of organizations nationally and internationally. They are included in some events in the athletics at the Summer Paralympics. The Dwarf Athletic Association of America and the Dwarf Sports Association UK provide opportunities for dwarfs to compete nationally and internationally in the Americas and Europe, respectively. The World Dwarf Games (WDG) are a multi-sport event for athletes of short stature. The WDG have been held every four years since 1993 and are the world's largest sporting event exclusively for athletes with dwarfism. The Dwarf Sports Association UK organizes between 5 and 20 events per month for athletes with restricted growth conditions in the UK. For instance, swimming and bicycling are often recommended for people with skeletal dysplasias, since those activities put minimal pressure on the spine. Since its early days, professional wrestling has had the involvement of dwarf athletes. "Midget wrestling" had its heyday in the 1950s–'70s, when wrestlers such as Little Beaver, Lord Littlebrook, and Fuzzy Cupid toured North America, and Sky Low Low was the first holder of the National Wrestling Alliance's World Midget Championship. In the next couple of decades, more wrestlers became prominent in North America including foreign wrestlers like Japan's Little Tokyo. Although the term is seen by some as pejorative, many past and current midget wrestlers including Hornswoggle said they take pride in the term due to its history in the industry and its marketability.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.